SCHEMBL8809979

SCHEMBL8809979

COc1cc2nccc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 5/20 0.72
EGFR P00533 5/20 0.68
RIPK2 O43353 2/20 0.67
EPHB2 P29323 1/20 0.67
PDGFRA P16234 4/20 0.66
ERBB2 P04626 1/20 0.66
GAK O14976 3/20 0.63
KDR P35968 3/20 0.63
BMPR1B O00238 1/20 0.63
EPHB6 O15197 1/20 0.63
ABL1 P00519 1/20 0.63
LCK P06239 1/20 0.63
SRC P12931 1/20 0.63
EPHA1 P21709 1/20 0.63
EPHA8 P29322 1/20 0.63
ACVR1 Q04771 1/20 0.63
MAP2K5 Q13163 1/20 0.63
COQ8A Q8NI60 1/20 0.63
NLK Q9UBE8 1/20 0.63
RAF1 P04049 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8933873 0.99 FGFR2 (0.70) FGFR2EGFRRIPK2EPHB2PDGFRA
SCHEMBL31123432 0.90 EGFR (0.69) FGFR2EGFRRIPK2EPHB2PDGFRA
SCHEMBL8501712 0.90 EGFR (0.74) FGFR2EGFRRIPK2PDGFRAGAK
Hydrochloric Acid SCHEMBL8933671 0.89 EGFR (0.67) FGFR2EGFRRIPK2EPHB2PDGFRA
SCHEMBL24143588 0.89 FGFR2 (0.81) FGFR2EGFRRIPK2PDGFRAGAK
SCHEMBL15607618 0.89 FGFR2 (0.58) FGFR2EGFRRIPK2EPHB2PDGFRA
SCHEMBL1387146 0.86 EGFR (0.62) FGFR2EGFRRIPK2EPHB2PDGFRA
Hydrochloric Acid SCHEMBL8933904 0.85 EGFR (0.62) FGFR2EGFRRIPK2EPHB2PDGFRA
Hydrochloric Acid SCHEMBL8808103 0.85 EGFR (0.61) FGFR2EGFRRIPK2EPHB2PDGFRA
SCHEMBL30017094 0.84 FGFR2 (0.61) FGFR2EGFRRIPK2PDGFRAGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10548897-B2 KSR antagonists ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-02-04 US disclosed
WO-2016168704-A1 KSR ANTAGONISTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2016-10-20 WO disclosed
EP-0782570-A1 SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE THE WELLCOME FOUNDATION LIMITED (GB) 1997-07-09 EP disclosed
WO-1996009294-A1 SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE THE WELLCOME FOUNDATION LIMITED (GB) 1996-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10548897-B2 KSR antagonists KSR1, KSR2, KRAS FGFR2 805/4885EGFR 182/4885RIPK2 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.